Methadone and buprenorphine are the only two opioids that are indicated for the management of both pain and opioid-related drug addiction. Both present unique challenges to the general practitioner and pain specialist, requiring a separate analysis from the rest of the drugs in the same family. Handbook of Methadone Prescribing and Buprenorphine Therapy is an invaluable guide to the safe use of these opioids. Authored by clinical and academic leaders from a variety of settings and backgrounds, this book includes chapters on pharmacology, adverse effects, safe rotation from other opioids, cardiac toxicity, prescribing, pharmacokinetics, equianalgesic dose and replacement therapy. This comprehensive text provides clinicians, researchers, policy-makers and academicians a resource for all the relevant points in methadone prescribing and buprenorphine therapy.

Managing infections that complicate care of neutropenic patients with leukemia and hematopoietic stem cell recipients has become a distinct specialty. In Managing Infections in Patients with Hematological Malignancies, the authors and editor draw on their extensive expertise while providing a roadmap for hematologists to efficiently manage the complex infections within their patients. The first section of the text reviews viral, bacterial, and fungal pathogens, and provides brief descriptions of the microbes and diseases they cause in patients with hematological malignancies. The second section is devoted to management of infections in patients with the different underlying hematological malignancies, while the third addresses several important topics that are often ignored in most books about infections and hematological malignancies. Managing Infections in Hematological Malignancies is a useful tool for all clinicians and practicing hematologists who treat individual patients and aspire to build stronger infectious diseases programs within their respective cancer centers.

Prostate Cancer: Biology, Genetics, and the New Therapeutics, Second Edition, reviews new, valuable approaches to the treatment of prostate cancer in men. The latest edition contains new material on molecular imaging, new treatments for prostate cancer, molecular targets, cell signaling pathways, bioinformatics, and pathogenomics. The book details the latest innovations and advances in prostate cancer and may be used as a rapid reference text for readers.

The volume profiles the latest advances in cancer research and treatment and includes profound studies in prostate stem cells, cancer-host interactions, hedgehog signaling in development and cancer, cholesterol and cell signaling, gene therapy for advanced prostate cancer, and noninvasive strategies such as molecular imaging to visualize gene expression. This new edition also investigates expression profiling and somatic alterations in prostate cancer progression and linkage studies of prostate cancer families to identify susceptibility genes. The issues of racial differences in prostate cancer mortality, radiotherapy for the treatment of locally advanced prostate cancer, recombinant antibody candidates for treatment, taxane-based chemotherapy, lethal phenotypes, and novel and efficient translation clinical trials are also presented in great depth.

Prostate Cancer: Biology, Genetics, and the New Therapeutics, Second Edition, provides readers with a general reference for prostate cancer from prevention to therapy and will be of value to clinicians, scientists, and administrators who strive to solve the cancer problem.

In this volume, the specific challenges and problems facing the evaluation of new oncology agents are explored with regards to pharmacokinetic, pharmacodynamic modeling and clinical pharmacology development strategies. This book delivers, with an emphasis on the oncology therapeutic area, the goals set in the first three volumes: namely - to provide clinical pharmacologists practical insights for the application of pharmacology, pharmacokinetics and pharmacodynamics for new drug development strategies. Pharmacokinetic-pharmacodynamic concepts for tyrosine kinases, the evaluation of cardiac repolarization prolongation through QTc interval effects, efficacy- and safety-response analyses to support new drug approvals, clinical and preclinical tumor growth modeling, and flat- vs weight-based dose selection are showcased from an oncology clinical pharmacologist's point-of-view. Oncology development strategies are surveyed for new FDA-approvals to identify patterns in expectations at time of first approval. The special considerations necessary to address combination drug development, metronomics, biosimilars and breakthrough therapies are also presented.

Current cancer therapies are focused on three general strategies: modifying intrinsic radiosensitivity via molecular targeting, manipulating microenvironmental factors to enhance tumor susceptibility to radiation, and improving delivery of radiation to critical tumor locations while sparing normal tissues. The goal of this volume is to describe a number of promising approaches corresponding to each strategy. In general, research in radiation oncology tends to be siloed into fundamental biology, physics or treatment delivery. The strategies for improving therapeutic ratio encompassed in this book will involve each of these components of radiation oncology. Thus, they will illustrate the variety of disparate approaches available for potentially improving the efficacy of radiotherapy, which may then stimulate discussion across disciplines and foster further translational investigations. Although a goal of each chapter will be to highlight advances within an approach, of equal importance will be the delineation of barriers to successful clinical application and how to overcome or minimize such impediments. Along these lines, because therapeutic ratio incorporates both tumor and normal tissue radio response, a point of emphasis will be the mechanistic rationale for selectively modifying tumor (sensitization) or normal cells (protection). Finally, whereas the literature is replete with studies describing potential targets/strategies for increasing the therapeutic ratio for radiotherapy, this book will focus on those supported by in vivo data consistent with impending translational application along with those that are already being evaluated in the clinic.

This interdisciplinary thesis introduces a systems biology approach to study the cell fate decision mediated by autophagy. A mathematical model of interaction between Autophagy and Apoptosis in mammalian cells is proposed. In this dynamic model autophagy acts as a gradual response to stress (Rheostat) that delays the initiation of bistable switch of apoptosis to give the cells an opportunity to survive. The author shows that his dynamical model is consistent with existing quantitative measurements of time courses of autophagic responses to cisplatin treatment. To understand the function of this response in cancer cells, he has provided a systems biology experimental framework to study quantitative and dynamical aspects of autophagy in single cancer cells using live-cell imaging and quantitative fluorescence microscopy. This framework can provide new insights on function of autophagic response in cancer cells.

This volume will introduce new terminology to the field of oncology, subdividing it into oncokinetics-the mechanics of the tumor cells as they arise and spread throughout the body-and oncodynamics-the impact of abnormal cues generated by tumors on the physiological functioning of the body. The volume will outline the importance of oncodynamics from both a cancer patient's and a caregiver's perspectives, stressing its significant impact on cancer patient functionality and the opportunity that cancer researchers will have to develop cross-disciplinary interactions and predict potential consequences of tumors and/or treatment.

High-fidelity chromosomal DNA replication underpins all life on the planet. In humans, there are clear links between chromosome replication defects and genome instability, genetic disease and cancer, making a detailed understanding of the molecular mechanisms of genome duplication vital for future advances in diagnosis and treatment. Building on recent exciting advances in protein structure determination, the book will take the reader on a guided journey through the intricate molecular machinery of eukaryotic chromosome replication and provide an invaluable source of information, ideas and inspiration for all those with an interest in chromosome replication, whether from a basic science, translational biology and medical research perspective.

The "Advances in Cancer Research" series provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents outstanding and original reviews on a variety of topics including RUNX Genes in Development and Cancer; The RNA Continent; The c-myc Promoter; Designer Self-Assembling Peptide Nanofiber Scaffolds for Study of 3-D Cell Biology and Beyond; and Dendritic Cells in Cancer Immunotherapy.

A panel of leading investigators summarizes and synthesizes the new discoveries in the rapidly evolving field of histone acetylation as a key regulatory mechanism for gene expression. The authors describe what has been learned about these proteins, including the identification of the enzymes, the elucidation of the enzymatic mechanisms of action, and the identification of their substrates and their partners. They also review the structures that have been solved for a number of enzymes-both alone and in complex with small molecule inhibitors-and the biological roles of the several histone deacetylases (HDAC) genes that have been knocked out in mice.

This thesis focuses on the development of gold- and non-classical platinum-based anti-cancer agents that display distinctively different anti-cancer mechanisms compared to the commonly used cisplatin. These metal complexes contain N-heterocyclic carbene (NHC) ligands which are able to form strong M-C(NHC) bonds, conferring high stability and favorable lipophilicity, reactivity and binding specificity of metal complexes on biomolecules. The author demonstrates significant advances made in anti-cancer gold(III), gold(I) and platinum(II) complexes. Detailed chemical synthesis, in vitro and/or in vivo anti-cancer activities are clearly presented including: (i) a class of Au(III) complexes containing a highly fluorescent N^N^N ligand and NHC ligand that simultaneously act as fluorescent thiol "switch-on" probes and anti-cancer agents; (ii) a dinuclear gold(I) complex with a mixed diphosphine and bis(NHC) ligand displaying favorable stability and showing significant inhibition of tumor growth in two independent mice models with no observable side effects; and (iii) a panel of stable luminescent cyclometalated platinum(II) complexes exhibiting high specificity to localize to the endoplasmic reticulum (ER) domain, inducing ER stress and cell apoptosis. These works highlight the clinical potential that gold and platinum complexes offer for cancer treatment.

This volume contains the main proceedings of the fourth international conference on "Cancer Prevention 2006," which was held during February 16 18, 2006, in St. Gallen, Switzerland. Written by international experts in the field, the book comprises a comprehensive update on the most recent developments in the upsurging fields of molecular biology and cancer genetics and their interactions with clinical epidemiology and cancer prevention at various levels.

Each year, almost twenty million people worldwide receive the grim diagnosis of cancer, yet few are prepared for the difficult emotional journey ahead. Shortly after Dr. Charles Hayter graduated as a cancer specialist, his father was diagnosed with terminal cancer. As with many doctors, he found that his medical training did not prepare him for the anguish and turmoil he witnessed in himself, his patients, and their loved ones - anguish often worsened by the stigma and shame surrounding cancer and radiation. In Cancer Confidential, Dr. Hayter shares behind-the-scenes stories of people dealing with cancer and death - often through avoidance, denial, and conflict, but also as shining examples of quiet courage, resilience, and humour. The backdrop for the stories is the specialty of radiation oncology. One in three cancer patients will receive radiation therapy, yet it remains a mysterious and often maligned area of medicine. Told in a vivid, dramatic style, Cancer Confidential sheds light on this poorly understood field and reveals intimate stories of individuals and their families in difficult circumstances. It will lend insight, compassion, and support to anyone facing the diagnosis of cancer.

In Apoptosis and Cancer: Methods and Protocols, Second Edition, expert researches in the field detail the performance of molecular and cellular biology techniques for studying and detecting the activation of the apoptotic pathway. Chapters focus on assays developed to detect its activation not only in vitro but also in vivo, optimized multiplex analysis, medium- to high-throughput screens, and the cellular process. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Apoptosis and Cancer: Methods and Protocols, Second Edition aids scientists as a stand-alone resource for the execution and analysis of the described protocols and as a reference for the study and detection of apoptosis within and outside the area of cancer research.

This volume explores the mechanisms of resistance to targeted therapeutics. The focus is on the cancer cell signaling network, although other mechanisms of resistance including target mutation, and new areas of study such as cancer stem cells are included. Targeted Therapies: Mechanisms of Resistance highlights examples of changes in the signaling network in response to inhibition of a signaling event and underscores the importance in having a mechanistic understanding of the signaling network in cancer for developing effective targeted cancer therapies. Moreover, cutting edge tools to analyze the cell signaling network will be discussed. This includes the leading edge of techniques as well as computational biology and systems theory. This volume provides the reader with both an overview as well as a detailed perspective on the mechanisms of resistance to targeted therapeutics and will be of great value to the oncologist, the physician-scientist treating patients and the translational scientist working on any aspect of targeted therapeutics.

In this book we have taken a comprehensive look at the subject of familial and hereditary gastric tumors. In particular, the aim of this novel editorial work is to propose the correct management of hereditary diffuse gastric cancer patients, focusing in particular on E-cadherin germline mutations, clinical criteria definition, genetic screening and molecular mechanisms, pathology and microscopic features, surgical treatment and clinical approach for asymptomatic mutation carriers. We also describe other inherited predispositions involving gastric carcinoma.

Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances brings together the three main pelvic specialties (Urology, Gynecological Oncology and Colorectal Surgery) into one volume. Patients have been shown to benefit from a multidisciplinary approach since it allows surgeons of different specialties to learn from one another therefore enhancing the treatment for the patient. Pelvic cancer outcomes are poor in low volume centres. These centres account for 80% of the global centres dealing with these cancers. Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances is a much needed book that can focus training and assist health professionals in their care of patients with pelvic dysfunction. Pelvic Cancer Surgery: Modern Breakthroughs and Future Advance is complete with full color illustrations and schematic diagrams and makes use of key points and stepwise figures for an enhanced learning experience.

Combined modularized therapies for metastatic cancer are pointing to central problems of communication among 'systems participators'. A communication theory explains 'social engineering', endogenously induced or by implementing non-normative boundary conditions. Evolution-adjusted tumor pathophysiology is borne by an evolution theory, which contrasts narrative evolution histories. The tool of rationalizations constituting the tumor's normativity (inflammation, immune response etc.) represents the non-genomic counterpart of the tumor genome and should be additionally assessed during tumor staging. Evolution-adjusted tumor pathophysiology allows implementing applied systems biology, a novel clinical and pharmaceutical technology for bioengineering tumor response and personalizing tumor therapy. Combined modularized therapy, evolution-adjusted tumor pathophysiology, and 'universal' biomarkers concertedly address genetically based tumor heterogeneity.

While many comprehensive texts have been written on the treatment of breast cancer, the most common cancer among women, there are relatively few which cover in depth the prevention and early detection of the disease. The goal of this work is to present what experts in the ?eld feel is the current knowledge and future direction of breast cancer prevention and early detection. We begin Part I of the book with a review of risk factors, both genetic and environmental. We next review progress in the use of chemoprevention. Notably, chemoprevention risk reduction studies have led to FDA approval of two medications which measurably reduce disease incidence among women at increased risk, although with some risk of treatment related side effects. Newer agents in the pipeline, which may also reduce risk among normal risk women, are also discussed. Surgical risk reducing strategies complete the section on prevention, including both the bene?ts and downsides to this more aggressive approach. Even with aggressive prevention strategies, some women will develop breast cancer. For these women, early detection is critical to minimize disease spread and maximize long term survival. Part II of this book reviews current and upcoming approaches to early detection. Imaging strategies, including mammography, breast ultrasound, MRI, and PET imaging are reviewed. The potential for molecular tumor targeting to detect disease prior to the formation of a mass visible by anatomic imaging is presented.

This book covers the scope of current knowledge of cancer in the LGBT community across the entire cancer continuum, from understanding risk and prevention strategies in LGBT groups, across issues of diagnosis and treatment of LGBT patients, to unique aspects of survivorship and death and dying in these communities. Each chapter includes an in depth analysis of the state of the science, discusses the many remaining challenges and unanswered questions and makes recommendations for research, policy and programmatic strategies required to address these. Focus is also placed on the diversity of the LGBT communities. Issues that are unique to cancer in LGBT populations are addressed including the social, economic and cultural factors that affect cancer risk behaviors, barriers to screening, utilization of health care services, and legislation that directly impacts the health care of LGBT patients, healthcare settings that are heterosexist and unique aspects of patient-provider relationships such as disclosure of sexual orientation and the need for inclusion of expanded definition of family to include families of choice. The implications of policy change, its impact on healthcare for LGBT patients are highlighted, as are the remaining challenges that need to be addressed. A roadmap for LGBT cancer prevention, detection, diagnosis, survivorship, including treatment and end of life care is offered for future researchers, policy makers, advocates and health care providers.

Lymphomas are lymphoid malignancies derived from B or T lymphocytes, and their study has been and still is paradigmatic for many aspects of cancer research. Lymphoma: Methods and Protocols presents and discusses key methods that are used in lymphoma research, partly specific for lymphoma research but often adaptable to the study of other cancers. By covering a broad variety of methods used in lymphoma research, this book will be of interest not only for hematologists, hematopathologists, and immunologists but also for scientists interested in other fields of cancer research as well as human genetics. Written in the highly successful Methods in Molecular Biology (TM) series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Versatile and cutting-edge, Lymphoma: Methods and Protocols serves researchers studying human physiology with the ultimate goal of understanding and controlling these often terrible diseases.